ELDN
Eledon Pharmaceuticals, Inc.
Healthcare · Biotechnology · NCM
$3.41
Data: 2026-05-13
✗ ETHICAL FAIL

MOAT
HIGH
Data Confidence: 100.0%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$299M
Total market value of the company
Trailing P/E
0.00
Forward P/E
-4.83
Based on estimated future earnings — lower means cheaper
Rev Growth
0.0%
Year-over-year revenue change
Profit Margin
0.0%
How much profit the company keeps from each dollar of revenue
ROE
-35.8%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$8.33
+144% from current price — median analyst estimate
Recommendation
STRONG_BUY
Consensus view from 6 analysts covering this stock
About Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

https://eledon.com

Country: United States Employees: 33 Industry: Biotechnology
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
0.2% PASS
Debt must be below 33% of total assets
Cash Ratio
44.5% FAIL
Interest-bearing cash below 33% of assets
Receivables
0.0% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime
ACCUMULATION
Smart money appears to be building positions quietly
Sharpe Ratio
0.697
Good returns relative to risk taken
Kelly Fraction
0.0106
Marginal edge — very small allocation suggested
Calmar Ratio
0.312
Drawdown risk outweighs the returns — higher risk profile
Annual Return
23.0%
Historical annualised return based on price data
Max Drawdown
-73.8%
Largest peak-to-trough decline — the worst it has been
HMM State
BULL
Statistical model sees bullish momentum
Days in State
115
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

Beta
0.95
Less volatile than the market — more defensive
52W High
$4.60
26% below the year high
52W Low
$1.35
153% above the year low
Avg Volume
1,471,166
Average daily shares traded — higher means easier to buy and sell
Short Ratio
4.5
Days it would take all short sellers to cover — higher means more crowded
Short % Float
9.8%
Moderate short interest
Div Yield
0.0%
Annual dividend as a percentage of the share price
EPS (TTM)
$-0.52
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity
0.47
Conservative use of debt — low financial risk
Current Ratio
8.44
Strong balance sheet — comfortably covers short-term obligations
Quick Ratio
8.30
Like current ratio but excludes inventory — stricter test
Gross Margin
N/A
Revenue left after cost of goods — higher means pricing power
Operating Margin
N/A
Profit from core operations before interest and tax
Free Cash Flow
$-39,672,500
Negative — the business is spending more than it generates
Revenue (TTM)
N/A
Total revenue over the last 12 months
Net Income
$-78,147,000
Loss-making — spending exceeds revenue after all costs
Analyst Coverage
Analysts
6
Target High
$12.00
Target Median
$8.33
Target Low
$5.00
Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date Insider Title Type Shares Value
2026-01-09 KATKIN KEITH A Director 8,575 —
2026-01-09 MCBRIDE JOHN S Director 3,430 —
2026-01-09 LEE JUNE YONG Director 3,430 —
2026-01-09 ROBINSON JAMES A JR. Director 3,430 —
2026-01-09 HILLSON JAN M.D. PH.D. Director 3,430 —
2026-01-09 KIRK ALLAN Director 3,430 —
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-13

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.